AUROPHARMA \u2014 Recent Activity

How The Aurobindo Pharma (NSEI:AUROPHARMA) Valuation Story Is Shifting Around Margins And Risk

Aurobindo Pharma’s fair value anchor in recent models has shifted from about ₹1,293.39 to roughly ₹1,366.07, providing an updated reference point for where some analysts see the stock’s central valuation. That change sits alongside an active debate about what is driving the revised estimate, with analysts weighing how adjustments to their assumptions affect the overall risk and reward profile. Read on to see what is shaping this evolving narrative and how you can track it over time. Stay...

Click to open →

Aurobindo Pharma Ltd (BOM:524804) Q3 2026 Earnings Call Highlights: Strong European Growth and ...

Aurobindo Pharma Ltd (BOM:524804) reports robust revenue growth driven by European operations and US injectable sales, while addressing regulatory challenges and strategic acquisitions.

Click to open →

India's Aurobindo Pharma posts higher profit on steady domestic demand

Feb 9 (Reuters) - Indian drugmaker Aurobindo Pharma reported a 7.6% rise in profit on Monday, helped by steady domestic demand, especially for its anti-retroviral drugs for HIV infections.

Click to open →

Update: BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump

(Updates with share price movement in headline and last paragraph). BioMarin Pharmaceutical (BMRN

Click to open →

BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 billion

BioMarin Pharmaceutical (BMRN) has agreed to acquire Amicus Therapeutics (FOLD) for $14.50 per share

Click to open →

Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and ...

Aurobindo Pharma Ltd (BOM:524804) reports robust revenue growth and operational efficiency, with significant contributions from European markets and strategic advancements in its biosimilar pipeline.

Click to open →

Aurobindo Pharma's profit rises on steady domestic demand 

(Reuters) -Indian drugmaker Aurobindo Pharma reported a 3.8% rise in profit on Wednesday, helped by steady domestic demand, especially for its anti-retroviral drugs for HIV infections.

Click to open →

Aurobindo Group's residential unit eyes $225 million India bond issue to fund acquisition

By Khushi Malhotra and Dharamraj Dhutia MUMBAI (Reuters) -India's Auro Realty, the real estate arm of Aurobindo Group which also owns drugmaker Aurobindo Pharma, is planning to raise 20 billion rupees

Click to open →

Private equity GTCR strikes $4.8 billion deal to buy Zentiva, FT reports

Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drugmaker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unidentified sources. Reuters could not immediately confirm the report. GTCR, Advent and Zentiva did not immediately respond to a Reuters request for comment.

Click to open →

India's Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports

Aurobindo is in talks with Zentiva's owner U.S.-based private equity firm Advent International, the report said, citing people aware of the matter. However, Aurobindo, in a statement to exchanges, said no binding agreements have been signed by the company's board. Advent International and Zentiva declined to comment on the report.

Click to open →